Chinese medical company Asclepius Meditec reported on Monday the availability of an environmentally friendly treatment generator AMS-H-03 involving the electrolysis of H2O to produce a mixture of hydrogen and oxygen for inhalation by COVID-19 patients with no side effects.
In a multicentered, open-label clinical trial, titled "Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial", the inhalation of the hydrogen/oxygen mixture prevented the further progression of the disease and, most notably, alleviated the shortness of breath experienced by COVID-19 patients. The results of the research as a treatment for COVID-19 were published in the June 2020 edition of the Journal of Thoracic Disease (JTD).
Asclepius Meditec added that the research and clinical trial was conducted on 44 patients with COVID-19 whose dyspnea could not be ameliorated after regular treatment in 11 hospitals. After three days of continuous use of the hydrogen/oxygen generator, AMS-H-03 , all 44 patients showed significant improvement compared with 46 patients who received the standard regimen of oxygen alone.
According to the company, the hydrogen/oxygen generator AMS-H-03 has received the Class III Medical Device certificate from China's National Medical Products Administration. The AMS-H-03 helps to reduce the mortality rate associated with COVID-19.
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Ipsen licenses Simcere Zaiming antibody-drug conjugate for global development
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Ipsen closes Phase II FALKON trial after missing primary endpoint in FOP
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study